Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Highlights from the latest articles in glioma immunotherapy.

Goldhoff P, Rubin JB.

Immunotherapy. 2010 Jan;2(1):9-12. doi: 10.2217/imt.09.73. No abstract available.

PMID:
20635886
[PubMed]
Free Article
2.

Research highlights: highlights from the latest articles in cancer immunotherapy.

Almubarak M, Abraham J.

Immunotherapy. 2012 May;4(5):473-5. doi: 10.2217/imt.12.30. No abstract available.

PMID:
22642329
[PubMed]
3.

Research highlights: highlights from the latest articles in immunotherapy.

Summers KL, Singh B.

Immunotherapy. 2012 Apr;4(4):363-4. doi: 10.2217/imt.12.27. No abstract available.

PMID:
22512628
[PubMed]
Free Article
4.

Novel immunotherapeutic approaches to glioma.

Yamanaka R.

Curr Opin Mol Ther. 2006 Feb;8(1):46-51. Review.

PMID:
16506525
[PubMed - indexed for MEDLINE]
5.

[Peptide vaccination therapy for malignant glioma].

Yamanaka R, Itoh K.

Brain Nerve. 2007 Mar;59(3):251-61. Review. Japanese.

PMID:
17370651
[PubMed - indexed for MEDLINE]
6.

Dendritic-cell- and peptide-based vaccination strategies for glioma.

Yamanaka R.

Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273. doi: 10.1007/s10143-009-0189-1. Epub 2009 Feb 13. Review.

PMID:
19214609
[PubMed - indexed for MEDLINE]
7.

Immunotherapy approaches for malignant glioma from 2007 to 2009.

Johnson LA, Sampson JH.

Curr Neurol Neurosci Rep. 2010 Jul;10(4):259-66. doi: 10.1007/s11910-010-0111-9. Review.

PMID:
20424975
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.

Chiba Y, Kinoshita M, Okita Y, Tsuboi A, Isohashi K, Kagawa N, Fujimoto Y, Oji Y, Oka Y, Shimosegawa E, Morita S, Hatazawa J, Sugiyama H, Hashimoto N, Yoshimine T.

J Neurosurg. 2012 Apr;116(4):835-42. doi: 10.3171/2011.12.JNS111255. Epub 2012 Jan 13.

PMID:
22242671
[PubMed - indexed for MEDLINE]
9.

Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.

Yang L, Ng KY, Lillehei KO.

Cancer Control. 2003 Mar-Apr;10(2):138-47. Review.

PMID:
12712008
[PubMed - indexed for MEDLINE]
Free Article
10.

Glioma immunology and immunotherapy.

Parney IF, Hao C, Petruk KC.

Neurosurgery. 2000 Apr;46(4):778-91; discussion 791-2. Review.

PMID:
10764250
[PubMed - indexed for MEDLINE]
11.

Dendritic cell-based glioma immunotherapy (review).

Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita M, Takahashi M, Tanaka R.

Int J Oncol. 2003 Jul;23(1):5-15. Review.

PMID:
12792771
[PubMed - indexed for MEDLINE]
12.

[State of the art in the treatment of cerebral gliomas].

Paoletti P, Butti G, Spanu G.

Minerva Med. 1992 Jan-Feb;83(1-2):17-24. Review. Italian.

PMID:
1545918
[PubMed - indexed for MEDLINE]
13.

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

Weller M, Fontana A.

Brain Res Brain Res Rev. 1995 Sep;21(2):128-51. Review.

PMID:
8866671
[PubMed - indexed for MEDLINE]
14.

Research highlights: highlights from the latest articles in optimizing vaccine development.

Lovett-Racke AE.

Immunotherapy. 2012 May;4(5):469-71. doi: 10.2217/imt.12.32. No abstract available.

PMID:
22642328
[PubMed]
15.

Research highlights: Highlights from the latest articles in regenerative medicine.

King CC, Sachlos E, Kerstetter-Fogle AE, Bollenbach T.

Regen Med. 2012 May;7(3):275-7. doi: 10.2217/rme.12.24. No abstract available.

PMID:
22594320
[PubMed]
16.

Research Highlights: highlights from the latest articles in nanomedicine.

Luby BM, Farhadi A, Shakiba M, Charron DM, Roxin A, Zheng G.

Nanomedicine (Lond). 2014 Apr;9(4):385-8. doi: 10.2217/nnm.13.216. No abstract available.

PMID:
24787437
[PubMed - in process]
Free Article
17.

Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.

Maes W, Van Gool SW.

Cancer Immunol Immunother. 2011 Feb;60(2):153-60. doi: 10.1007/s00262-010-0946-6. Epub 2010 Dec 1. Review.

PMID:
21120655
[PubMed - indexed for MEDLINE]
18.

Research highlights: highlights from the latest articles on the pharmacogenomics of neuropsychiatric disorders.

Lorenzi C, Pirovano A, Bosia M.

Pharmacogenomics. 2014 Apr;15(6):735-8. doi: 10.2217/pgs.14.23. No abstract available.

PMID:
24897281
[PubMed - in process]
19.

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy.

Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B.

Br J Cancer. 2007 Apr 23;96(8):1293-301. Epub 2007 Mar 20. Erratum in: Br J Cancer. 2007 Jun 18;96(12):1928.

PMID:
17375044
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

[Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].

Kubo O, Takakura K.

Nihon Rinsho. 2002 Mar;60(3):497-503. Review. Japanese.

PMID:
11904965
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk